KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.

Haixia Guan, Hongwei Jiang, Huijuan Yuan, Jie Sun, Jiawei Xu, Linong Ji

Diabetes Obes Metab 27(11) 6480-6490

PMID40926359
PMCIDPMC12515763
DOI10.1111/dom.70047
发表日期2025-09-10
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other。
摘要

摘要

AIM: To evaluate the long-term efficacy and safety data at 104 weeks in tirzepatide-treated participants with type 2 diabetes who had inadequate glycaemic control on metformin and/or sulfonylurea. MATERIALS AND METHODS: This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial. Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine. The primary efficacy endpoint was change in HbA1c levels from baseline to 104 weeks. Key secondary endpoints were changes in body weight and the proportion of participants achieving HbA1c <7.0%. Safety endpoints included the incidence of treatment-emergent adverse events (AEs) and hypoglycaemia. RESULTS: This post-hoc analysis included 1,500 participants. At Week 104, participants in the tirzepatide groups had significantly greater mean reduction in HbA1c (5 mg: -2.3%, 10 mg: -2.5%, 15 mg: -2.6%) compared with the insulin glargine group (-1.0%) (p < 0.001). Participants in the tirzepatide groups had significantly greater reduction in body weight (5 mg: -7.6 kg, 10 mg: -10.0 kg, 15 mg: -11.4 kg) compared with the insulin glargine group (2.1 kg) (p < 0.001). Significantly more participants in the tirzepatide group achieved HbA1c <7.0% compared with the insulin glargine group (p < 0.001). The incidence of hypoglycaemia was lower in the tirzepatide groups, and gastrointestinal AEs were mild or moderate in severity. CONCLUSIONS: Tirzepatide significantly improved glycaemic control and body weight reduction compared to insulin glargine over 104 weeks in participants with type 2 diabetes inadequately controlled on metformin and/or sulfonylurea. The safety profile of tirzepatide was acceptable, with a lower incidence of hypoglycaemia than insulin glargine.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Treatment comparison of tirzepatide 5, 10 and 15 mg versus insulin glargine in study population for change in HbA1c. (A) Mean change in HbA1c from baseline to 104 weeks. (B) Proportion of participants achieving HbA1c targets at 104 weeks. (C) Absolute HbA1c over time from baseline to 104 weeks in the study population. *** p < 0.001 versus insulin glargine; p values shown are for within treatment for HbA1c over time in (1); n in (A) is number of participants at baseline and n in (B) is number of participants at 104 W. Only participants with non‐missing baseline value and at least one non‐missing post‐baseline value of the response variable were included in analysis. HbA1c, glycated haemoglobin; LS mean, least squares mean; SE, standard error.
非 KM Figure
FIGURE 2FIGURE 2 Treatment comparison of tirzepatide 5, 10 and 15 mg versus insulin glargine in participants with diabetes for change in body weight. (A) LS mean change in body weight over time from baseline to 104 weeks. (B) Body weight over time from baseline to 104 weeks in the study population. (C) Proportion of participants achieving weight reduction targets at 104 weeks. *** p < 0.001 versus insulin glargine; p values shown are for within treatment for body weight over time in (B); n indicated in (A) is number of participants at baseline and n in (C) is number of participants at 104 W. Only participants with non‐missing baseline values and at least one non‐missing post‐baseline value of the response variable were included in the analysis. LS mean, least squares mean; SE, standard error.
非 KM Figure